JMP Securities analyst reaffirmed a positive outlook on Larimar Therapeutics (NASDAQ:LRMR), maintaining a Market Outperform ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

Carl's away, so I've punched out a bite-sized Evening Wrap ASX 200 ticked higher and finished the week up 1.19% Wesfarmers shares soared after a Goldman Sachs upgrade Let's dive in. Today in Review ...

Morgans analyst Scott Power says there's been a rotation back into small healthcare stocks as EBR Systems records a massive ... Read More The post Scott Power: Cardiac pacing device developer EBR hits ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...

Sandip Kapadia, the Chief Financial Officer of Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), a pharmaceutical company ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in tandem thanks to advancements in technology and a growing body of research on ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.